Clarient to Present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17th

Presentation Scheduled for 8:45am EDT 


ALISO VIEJO, Calif., March 12  /PRNewswire-FirstCall/ -- Clarient, Inc. (NASDAQ:CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Ron Andrews, CEO and Vice Chairman, is scheduled to make an investor presentation at the Cowen and Company 29th Annual Health Care Conference at 8:45 a.m. EDT on Tuesday, March 17, 2009.  The conference will be held at The Boston Marriott Copley Place from March 16-19, 2009.

A live webcast of the presentation will be available via a link provided at http://www.clarientinc.com/investor.  An archived replay of the presentation will be available for a period of 90 days.

About Clarient

Clarient combines innovative technologies with world-class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. http://www.clarientinc.com/

About Safeguard

Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices, Regenerative Medicine and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. http://www.safeguard.com/

  Contact:
  Matt Clawson
  Allen & Caron, Inc.
  [phone]
  

DATASOURCE: Clarient, Inc.



CONTACT:  Matt Clawson  of Allen & Caron, Inc., [phone],

, for Clarient, Inc.



Web Site:  http://www.clarientinc.com/ 

Copyright